drugset / Trial / NCT00216866

The Catheter Study: Central Venous Catheter Survival in Cancer Patients Using Low Molecular Weight Heparin (Dalteparin) for the Treatment of Deep Vein Thrombosis

NCT00216866

Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to obtain an estimate of catheter survival in the setting of upper extremity deep vein thrombosis (UEDVT) in patients treated with dalteparin and warfarin. Anticoagulation with dalteparin and warfarin in patients with UEDVT secondary to central venous catheters in patients with an active malignancy is an effective therapy as quantified by the success of catheter preservation. A prolonged line salvage rate without a recurrence of UEDVT will improve the management of cancer patients who develop upper extremity deep venous thrombosis in the setting of a central venous (CV) catheter.

Timeline

Start
2002-09
Primary completion
2006-03
Completion
2006-03

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Dalteparin sodium Other / unclassified
Subject Warfarin Small molecule